Bausch Health
| Bausch Health Companies Inc.
|
|
|---|---|
 |
|
| legal form | Corporation |
| ISIN | CA0717341071 |
| founding | 1960/1982 |
| Seat |
Laval , Canada
|
| management | Joseph C. Papa, management spokesman |
| Number of employees | 22,000 (2017) |
| sales | US $ 5.76 billion (2013) |
| Website | bauschhealth.com |
Bausch Health (formerly Valeant Pharmaceuticals International ) is an international pharmaceutical company headquartered in Laval in the province of Québec near Montreal (Canada). Bausch Health is traded on the Toronto Stock Exchange ( TSX ) and the New York Stock Exchange ( NYSE ) under the symbol "BHC". It researches, develops and produces pharmaceuticals and markets patented drugs, generics and non-prescription drugs in the areas of dermatology and ophthalmology .
The company was founded in 1960 and in 2013 had 7,500 employees and worldwide sales of approximately 5.8 billion US dollars.
The Swedish pharmaceutical company Meda AB acquired Valeant businesses in Western and Eastern Europe for US $ 392 million in 2008. Thereby exists u. a. also no longer a German subsidiary. The former Valeant products are meanwhile distributed in Germany by MEDA Pharma Germany (Bad Homburg).
In 2010 Valeant merged with the Canadian pharmaceutical company Biovail , and the Biovail Corporation was renamed Valeant. In May 2013, the US company Bausch & Lomb was sold to Valeant. In 2015, the company announced that it would acquire competitor Salix Pharmaceuticals for $ 14.5 billion. For Valeant, this is the largest acquisition in the company's history. In August, Valeant and Sprout Pharmaceuticals announced that they had agreed to acquire Sprout by Valeant. In the fourth quarter of the year, a subsidiary of Valeant should take over the company Sprout for around one billion US dollars. At the same time, Sprout gained media attention with the drug Addyi ("Viagra for women").
On October 21, 2015, Valeant was suspected of manipulating his balance sheets. The share then lost 40 percent of its value and was temporarily suspended from trading. The price loss from mid-September 2015 to April 2017 was more than 95 percent. As a result of the accounting scandal, the group management was changed in 2016 and the name was changed to Bausch Health Companies in July 2018.
Web links
- Bausch Health (English)
- MEDA Pharma Germany
- Salix Pharmaceuticals (English)
- Sprout Pharmaceuticals
Individual evidence
- ^ Valeant: Board of Directors . 2014. Retrieved March 25, 2014.
- ↑ a b c d e Valeant: Key Facts & History . 2014. Retrieved March 25, 2014.
- ↑ Sweden's Meda AB (SE: MEDAa) Buys American Valeant Pharmaceuticals International (VRX) Units for $ 392 Million ( Memento of the original from October 11, 2014 in the Internet Archive ) Info: The archive link was automatically inserted and not yet checked. Please check the original and archive link according to the instructions and then remove this notice.
- ↑ Pharmaceutical company Valeant grabs Bausch & Lomb. Article in Manager Magazin online , May 27, 2013.
- ↑ Bausch & Lomb sold for $ 8.7 billion. Article on the ORF website , May 27, 2013.
- ↑ Valeant takes over competitor Salix published on Handelsblatt.de on February 23, 2015
- ↑ Pharma giant Valeant accused of fraud Report in Business Inside magazine of October 21, 2015, accessed on December 24, 2017
- ↑ Valeant shares temporarily suspended from trading Report in Finanz.net of October 22, 2015, accessed on December 24, 2017
- ↑ https://www.apotheke-adhoc.de/nachrichten/detail/markt/valeant-wird-bausch/
